Using lipid nanoparticles to deliver genetic treatments to eye cells
Delivering genetic medicines to photoreceptors with lipid nanoparticles
This study is exploring a new way to deliver genetic treatments directly to the eye's light-sensitive cells to help fix genetic problems that cause vision loss, using tiny bubbles to safely carry the medicine and a special tool to make corrections.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enterx Biosciences, INC. NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10821043 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to deliver genetic medicines specifically to photoreceptor cells in the eye, which are crucial for vision. The approach utilizes lipid nanoparticles, which are tiny bubbles made of lipids that can safely carry genetic material into cells. By employing the CRISPR-Cas9 technology, the goal is to correct genetic mutations that lead to inherited retinal diseases, potentially restoring vision. This innovative delivery system aims to overcome the limitations of current viral gene therapies, which can provoke immune responses and have size restrictions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inherited retinal diseases caused by specific genetic mutations.
Not a fit: Patients with retinal diseases not linked to genetic mutations or those whose conditions are not amenable to genetic correction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for inherited retinal diseases, potentially restoring vision for millions of affected individuals.
How similar studies have performed: While gene therapy approaches have been explored, the specific use of lipid nanoparticles for targeted delivery to photoreceptors is a novel approach that has shown promising initial results.
Where this research is happening
Portland, United States
- Enterx Biosciences, INC. — Portland, United States (Active)
Researchers
- Principal investigator: Tuttle, Adam — Enterx Biosciences, INC.
- Study coordinator: Tuttle, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.